RxDoctor Payments Data

Scott Wegner, MD

Medical Oncology · Zanesville, OHNPI 1699729434

Payments from drug & device makers

What this record shows

This record is dominated by education: $495 of the $610 with a category attached, or 81.1%. 8 manufacturers reported payments, led by Exelixis Inc. at 45.1% of the total. Reporting peaked in 2019 at $316 and has fallen 68.6% since, to $99 in 2025. That places this record below the midpoint for medical oncology clinicians in OH, where the typical reported total is $2,659.

$610in general payments, 2019–2025

Across 21 payments — averaging $29.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exelixis Inc.$275
  • Johnson & Johnson$117
  • Pharmaessentia USA Corporation$70
  • Pfizer$67
  • Novartis$29
  • Myovant Sciences Inc.$24
  • plus $28 from 2 others
$5,197in research payments, 2019–2025

Across 7 payments — averaging $742.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$4K
  • E.r. Squibb & Sons, L.L.C.$750

What the payments were for

  • Food & beverage$11519%
  • Education$49581%

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$610 in reported general payments places this provider in the 30th percentile of 157 medical oncology providers in Ohio.

See all medical oncology providers in Ohio →

Medicare billing

Part B allowed, 2024
$64,211
Medicare patients
328
Services billed
655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib50$817,363
CabometyxCabozantinib S-Malate30$701,115
Abiraterone Acetate147$604,696
Lenalidomide36$539,168
BrukinsaZanubrutinib35$446,285
JakafiRuxolitinib Phosphate18$340,816
CalquenceAcalabrutinib Maleate22$318,783
PomalystPomalidomide14$312,590
XtandiEnzalutamide22$273,337
IbrancePalbociclib14$224,745
LonsurfTrifluridine/Tipiracil Hcl15$195,560
LorbrenaLorlatinib11$181,553
VenclextaVenetoclax14$171,404
EliquisApixaban37$35,674
XareltoRivaroxaban40$29,761

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Exelixis Inc.Cabometyx$275$701,11530 claims
PfizerIbrance, Lorbrena, Eliquis$67$441,97262 claims
Johnson & JohnsonXarelto$117$29,76140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 157 medical oncology providers in Ohio.

Other medical oncology in Zanesville

See the full list for Ohio →

Where these figures come from

Is this you, or does something look wrong? →